| Literature DB >> 24381259 |
Lei Liu1, Jin Geng, Jingyang Wu, Zhe Yuan, Jie Lian, Huang Desheng, Lei Chen.
Abstract
OBJECTIVE: To describe the telescreening model and assess the prevalence of ocular fundus pathology in patients with type 2 diabetes within a Chinese urban community.Entities:
Year: 2013 PMID: 24381259 PMCID: PMC3884592 DOI: 10.1136/bmjopen-2013-004146
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Categorisation of the different types of fundus pathology identified in 223 of the 528 patients with type 2 diabetes mellitus*
| Fundus pathology | Number of patients (%) | Number of patients with newly detected pathology (%) |
|---|---|---|
| Signs of DR | 75 (14.20) | 65 (86.67) |
| Signs of glaucoma | 63 (11.93) | 53 (84.13) |
| Signs of AMD | 57 (10.79) | 48 (84.21) |
| Sign of DR and glaucoma | 9 (1.70) | 6 (66.67) |
| Sign of DR and AMD | 6 (1.13) | 6 (100) |
| Sign of glaucoma and AMD | 2 (0.38) | 2 (100) |
| Sign of DR, glaucoma and AMD | 1 (0.19) | 1 (100) |
| Other pathology (including pathological myopia, retinal vessel occlusion, optic nerve atrophy, macular hole, etc) | 28 (5.30) | 9 (32.14) |
*Some patients may have had more than one fundus pathology.
AMD, age-related macular degeneration; DR, diabetic retinopathy.
Demographic and clinical characteristics of the 528 patients with type 2 DM
| All participants | All patients with fundus pathology | Patients with signs of DR | Patients with signs of glaucoma | Patients with signs of AMD | |
|---|---|---|---|---|---|
| Age (years), n (%) | 528 | 223 (42.23) | 75 (14.20) | 63 (11.93) | 57 (10.79) |
| 45–54 | 186 (35.23) | 71 (31.84) | 32 (33.33) | 19 (30.16) | 11 (19.30) |
| 55–64 | 224 (42.42) | 89 (39.91) | 36 (57.33) | 32 (50.79) | 14 (24.56) |
| >65 | 118 (22.35) | 63 (28.25) | 7 (9.33) | 12 (19.05) | 32 (56.14) |
| Sex, n (%) | |||||
| Females | 287 (54.36) | 118 (52.91) | 44 (58.67) | 41 (65.79) | 25 (43.86) |
| Males | 241 (45.64) | 105 (47.09) | 31 (41.33) | 22 (34.21) | 32 (56.14) |
| Smoking, n (%) | |||||
| Yes | 309 (58.52) | 128 (57.34) | 42 (56) | 31 (49.21) | 37 (64.91) |
| No | 219 (41.48) | 95 (42.66) | 33 (44) | 32 (50.79) | 20 (35.09) |
| Alcohol consumption, n (%) | |||||
| Yes | 359 (67.99) | 119 (53.36) | 36 (48) | 29 (46.03) | 26 (45.61) |
| No | 169 (32.01) | 104 (46.64) | 39 (52) | 34 (53.97) | 31 (54.39) |
| Duration of DM (years), n (%) | |||||
| <5 | 184 (34.85) | 59 (26.46) | 19 (25.33) | 17 (26.98) | 16 (28.07) |
| 6–15 | 220 (41.67) | 91 (40.81) | 24 (32) | 21 (33.33) | 17 (29.82) |
| >16 | 118 (22.35) | 73 (32.73) | 32 (42.67) | 25 (39.69) | 24 (42.11) |
| Hypertension, n (%) | |||||
| Present | 365 (69.13) | 112 (50.22) | 49 (65.33) | 28 (44.44) | 29 (50.88) |
| Absent | 163 (30.87) | 111 (49.78) | 26 (34.67) | 35 (55.56) | 28 (49.12) |
| DM controlled, n (%) | |||||
| Yes | 315 (59.66) | 132 (59.19) | 41 (54.67) | 38 (60.32) | 31 (54.39) |
| No | 213 (40.34) | 91 (40.81) | 34 (45.33) | 25 (39.68) | 26 (45.61) |
| IOP, mm Hg, mean±SD | 18.87±5.78 | 19.76±3.54 | 18.15±2.94 | 25.33±3.19 | 16.91±2.15 |
| FPG, mmol/L, mean±SD | 8.96±2.34 | 9.92±4.33 | 11.03±3.37 | 8.02±2.43 | 8.45±1.18 |
| TG, mmol/L, mean±SD | 1.89±0.65 | 1.94±0.56 | 1.98±0.54 | 1.66±0.44 | 1.81±0.32 |
| TC, mmol/L, mean±SD | 5.27±1.78 | 6.02±1.34 | 5.89±1.21 | 5.09±1.01 | 4.99±1.44 |
| HbA1c (%) | 7.99 | 11.92 | 12.21 | 6.01 | 5.98 |
Statistical methods: independent samples t test or χ2 test.
DM controlled was defined as insulin injection therapy or antidiabetic drug to be taken orally.
AMD, age-related macular degeneration; DM, diabetes mellitus; DR, diabetic retinopathy; FPG, fasting plasma glucose; HbA1c, concentration of glycated haemoglobin; IOP, intraocular pressure; TG, triglycerides; TC, total cholesterol.
Risk factors for fundus pathology in patients with type 2 DM as assessed by logistic regression analysis
| All patients with fundus pathology | p Value | Patients with signs of DR | p Value | Patients with signs of glaucoma | p Value | Patients with signs of AMD | p Value | |
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |||||
| Age (years) | – | – | ||||||
| 45–54 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| 55–64 | 0.79 (0.51 to 1.12) | 0.06 | 0.52 (0.21 to 0.78) | 0.01 | 1.08 (0.35 to 1.71) | 0.06 | 0.79 (0.63 to 0.86) | <0.001 |
| >65 | 1.21 (0.91 to 1.98) | 0.07 | 0.48 (0.32 to 0.52) | 0.02 | 1.52 (0.71 to 2.78) | 0.07 | 1.29 (1.11 to 1.32) | <0.001 |
| Sex | ||||||||
| Females | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Males | 0.68 (0.53 to 0.73) | 0.01 | 0.78 (0.62 to 0.84) | 0.01 | 0.53 (0.42 to 0.61) | <0.001 | 0.61 (0.54 to 0.71) | 0.01 |
| Smoking | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 0.89 (0.82 to 1.02) | 0.06 | 2.88 (1.79 to 3.91) | <0.001 | 1.88 (0.62 to 2.31) | 0.10 | 1.18 (0.87 to 1.38) | 0.07 |
| Alcohol consumption | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 1.12 (0.86 to 1.31) | 0.06 | 1.98 (1.49 to 2.96) | <0.001 | 0.97 (0.62 to 1.34) | 0.06 | 2.08 (0.97 to 3.93) | 0.01 |
| Duration of DM (years) | ||||||||
| <5 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| 6–15 | 1.98 (1.29 to 2.97) | <0.001 | 1.93 (1.39 to 2.87) | <0.001 | 1.28 (1.09 to 1.47) | 0.003 | 1.19 (1.02 to 1.37) | <0.001 |
| >16 | 2.31 (1.87 to 2.56) | <0.01 | 2.45 (1.65 to 3.16) | <0.01 | 0.99 (0.87 to 1.16) | 0.07 | 2.31 (1.87 to 2.56) | 0.01 |
| Hypertension | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 1.18 (0.97 to 1.54) | 0.06 | 1.32 (1.29 to 1.66) | 0.001 | 2.18 (1.39 to 2.94) | 0.03 | 0.81 (0.49 to 1.34) | 0.10 |
| DM controlled | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 1.84 (0.88 to 2.35) | 0.21 | 1.12 (0.38 to 2.15) | 0.12 | 1.14 (0.58 to 2.23) | 0.14 | 0.92 (0.55 to 1.55) | 0.09 |
| IOP >21 mm Hg | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 1.85 (0.38 to 3.15) | 0.21 | 1.21 (0.56 to 1.75) | 0.11 | 3.84 (2.85 to 4.66) | 0.01 | 0.89 (0.81 to 1.25) | 0.23 |
| FPG >7 mmol/L | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 3.64 (1.81 to 5.21) | <0.001 | 2.55 (1.85 to 4.15) | 0.03 | 1.81 (0.82 to 3.15) | 0.22 | 2.82 (0.58 to 4.54) | 0.28 |
| TG >1.7 mmol/L | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 0.83 (0.55 to 1.38) | 0.08 | 1.54 (0.78 to 2.33) | 0.07 | 1.31 (0.96 to 1.67) | 0.09 | 3.83 (0.25 to 6.15) | 0.26 |
| TC >5.5 mmol/L | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 2.24 (0.75 to 3.15) | 0.11 | 1.11 (0.55 to 2.44) | 0.18 | 0.89 (0.51 to 2.42) | 0.27 | 1.14 (0.66 to 2.37) | 0.21 |
| HbA1c >7% | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 3.83 (1.87 to 6.35) | <0.001 | 3.12 (1.18 to 7.15) | 0.001 | 1.12 (1.08 to 1.75) | 0.01 | 1.22 (1.01 to 1.73) | 0.02 |
Statistical method: logistic regression analysis.
AMD, age-related macular degeneration; DM, diabetes mellitus; DR, diabetic retinopathy; FPG, fasting plasma glucose; HbA1c, concentration of glycated haemoglobin; IOP, intraocular pressure; TG, triglycerides; TC, total cholesterol..
DM controlled was defined as insulin injection therapy or antidiabetic drug to be taken orally.
Studies that have investigated the prevalence of fundus pathology in patients with type 2 DM in urban or community settings
| Study (country) | Number of patients with DM | Study design | Type of DM | Prevalence | Risk factors |
|---|---|---|---|---|---|
| Any DR | |||||
| Shanghai Diabetic Complications Study (China) | 3736 | Cross-sectional, community based | NA | 9.4% | Hyperglycaemia |
| The Beijing Communities Diabetes Study (China) | 2007 | Cross-sectional study | Type 2 | 24.7±1.0% | Long duration of diabetes; high-HbA1c levels; high-systolic blood pressure; elevated blood urea concentration; microalbuminuria |
| Epidemiological study of DR in Hong Kong (Hong Kong) | 4423 | Retrospective community-based study | Type 2 | 28.4% | Glycated haemoglobin level |
| Prevalence and determinants of DR (Qatar) | 540 | Community-based survey | Type 2 | 23.5% | Long duration of DM; poor glycaemic control |
| Prevalence of DR in Lampang (Thailand) | 3049 | Cross-sectional study | NA | BDR or NPDR was 18.9% and PDR was 3% | Long duration of DM |
| Glaucoma | |||||
| The Los Angeles Latino Eye Study (USA) | 1157 | Cross-sectional study | Type 2 | Long duration of DM | |
| Singapore Malay Eye Study (Singapore) | 764 | Population-based study | NA | 4.7% | Not associated |
| AMD | |||||
| DR and AMD study (Korea) | 315 | Cross-sectional study | NA | 5.4% | NA |
| The EUREYE study (Greece) | 616 | Cross-sectional study | NA | 13.1% | NA |
AMD, age-related macular degeneration; BDR, background diabetic retinopathy; DM, diabetes mellitus; DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; NA, not applicable PDR, proliferative diabetic retinopathy;.